Center for Research in Security Prices, LLC

UChicago Medicine Comprehensive Cancer Center aims to use AI, machine learning, and high-performance computing to develop new treatments for drug-resistant cancer, funded by ARPA-H. The $15 million project, IDEAL, leverages Argonne National Laboratory's supercomputing capabilities to accelerate drug discovery for ovarian cancer and potentially other cancers.

Theragent Inc. produced the first batch of autologous cancer vaccine for CellVax Therapeutics' Phase 2 trial, FK-PC101, targeting high-risk prostate cancer recurrence. The trial, CELLVX-230, is a multicenter, adaptive, randomized, open-label study conducted in partnership with SUO-CTC, with Theragent handling end-to-end manufacturing.

UChicago researchers developed a solvent exchange process to create a hydrogel semiconductor, combining properties of both materials to improve biological functions, reducing immune responses and enhancing biosensing and therapeutic effects.

MAIA Biotechnology, Inc. announced that independent director Stan V. Smith, Ph.D. purchased 100,000 shares and warrants of MAIA’s common stock for $225,900 in a recent private placement.

Stanford Institute for Human-Centered AI announces 29 graduate and postdoctoral fellows for 2024-25, representing diverse research areas including AI safety, digital health, energy science, and precision medicine. Fellows will collaborate with Stanford faculty on human-centered AI challenges.

MAIA Biotechnology, Inc. announced that independent director Stan V. Smith, Ph.D. purchased 100,000 shares and warrants of the company's common stock for $225,900 as part of a recent private placement. Smith, a long-time investor, believes in the potential of MAIA's THIO franchise for treating various cancer types.

MAIA Biotechnology announced that independent director Stan V. Smith, Ph.D., purchased 100,000 shares of common stock and warrants to purchase an additional 100,000 shares for a total of $225,900 in the company's recent private placement, closed on November 1, 2024. Smith, an original investor, has participated in nearly every private placement financing round since MAIA's inception, expressing confidence in the THIO franchise's potential in treating multiple difficult-to-treat cancer types through telomere targeting and immunogenicity.

ASHG welcomed 2024–2026 Human Genetics Scholars, including Amber M. Abram, Kynon J. Benjamin, Razaq Durodoye, Tania Fabo, Gabrielle Ferra, JP Flores, Renée Fonseca, and Esteban Vazquez-Hidalgo, recognized for research and commitment to diversity, equity, and inclusion in human genetics and genomics.

Genetic mutations, including those from environmental carcinogens, disrupt cell functions, leading to cancer. Researchers at UChicago analyze air pollution data and find higher cancer risks linked to air pollutants, with varying impacts by race/ethnicity. Studies also explore cellular and genetic impacts of environmental factors, aiming to identify new cancer prevention strategies. Population-level data is crucial for understanding environmental health, informing policy decisions and public health programs.

World War II sugar rationing in the UK led to lifelong health benefits for children, showing up to 35% lower risk of type 2 diabetes and 20% lower risk of high blood pressure. This natural experiment highlights the long-term effects of early-life sugar exposure on health.